Abstract
Objective
Transcatheter Arterial Chemoembolization (TACE) is the first choice for the treatment of advanced-stage hepatocellular carcinoma (HCC). However, TACE suffers from a lack of specificity and rapid drug release. Herein, a targeted redox-responsive peptide (TRRP) was synthesized and used as a carrier of doxorubicin (DOX) to enhance the efficacy of TACE through tumor cells targeting and controlled drug release.
Methods
TRRP has a high loading capacity of DOX and a sensitive drug release behavior at high glutathione (GSH) concentration. Moreover, TRRP could bind to the transferrin receptor on the surface of tumor cells, which enhanced the efficacy of TACE and reduced side effects of TACE. TACE with TRRP@DOX dispersed in lipiodol shows an enhanced therapeutic outcome compared to the treatment with DOX + lipiodol emulsion in orthotopic rat HCC models.
Results
TRRP has a high loading capacity of DOX and a sensitive drug release behavior at GSH concentration. Moreover, TRRP could bind to the transferrin receptor on the surface of tumor cells, which enhanced the efficacy of TACE and reduced side effects of TACE. TACE with TRRP@DOX dispersed in lipiodol shows an enhanced therapeutic outcome compared to the treatment with DOX + lipiodol emulsion in orthotopic rat HCC models.
Conclusions
This study demonstrated that TRRP was a promising therapeutic agent for enhancing TACE therapy for HCC treatment.
Graphical abstract
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Hepatocellular carcinoma (HCC) is a major concern worldwide, ranking fifth in new cases and third in mortality rates [1,2,3]. It often goes undetected until later stages, with fewer than 20% of patients suitable for surgical removal [4,5,6]. Although systemic chemotherapy is an option, it hasn’t shown substantial benefits for HCC patients and comes with severe side effects [7,8,9].
Recently, Lipiodol-based transcatheter arterial chemoembolization (TACE) has become the main palliative treatment for inoperable HCC, showing significant effectiveness in intermediate and advanced cases [10, 11]. However, TACE has limitations. Firstly, its lack of specificity raises concerns as it may harm healthy liver tissues [12, 13]. Secondly, there are challenges in controlling drug release within the tumor site using both natural and external triggers [14, 15]. Thus, there’s an urgent need for an innovative drug delivery system to improve TACE’s efficacy. Incorporating multifunctional nanomaterials into TACE shows promise in overcoming these obstacles [16,17,18]. These nanomaterials can carry drugs, target specific sites, and release drugs in response to stimuli, making them suitable for TACE [19, 20]. However, their preparation process is often complex and their toxicity raises concerns [21,22,23,24]. Peptides, due to their safety profile, stand out as potential carriers for drugs. They can be synthesized quickly, controlled precisely, and enhanced with specific ligands for targeted delivery, minimizing risks to non-target cells and facilitating drug elimination [25,26,27,28]. The transferrin receptor (TfR) is crucial in cellular iron uptake, overexpressed on liver cancer cells’ surface, making it a potential target for drug delivery [29,30,31,32]. Additionally, liver cancer cells have high intracellular glutathione levels, suggesting potential targeting opportunities [33, 34].
To address the challenges in TACE, we propose an innovative approach: the synthesis of reductively responsive self-assembled peptides targeting hepatoma cells using solid-phase synthesis. This strategy, named Targeted Redox-Responsive Peptide (TRRP), selectively targets overexpressed transferrin receptors on liver cancer cell surfaces [35,36,37]. Additionally, it possesses redox-responsive characteristics, enabling drug release within tumor cells when exposed to elevated levels of glutathione [38, 39]. Moreover, it demonstrates exceptional biocompatibility [40]. We thoroughly examined TRRP’s physicochemical properties using spectroscopy and electron microscopy analysis. Rat McA-RH7777 liver tumor models, resembling human HCC, were established, and DOX-loaded TRRP (TRRP@DOX) was administered through the hepatic artery in TACE. Through blood biochemistry analysis, dynamic MRI, and endpoint pathological and immunohistochemical evaluations, our research suggests that peptides enhance TACE’s effectiveness in liver cancer treatment while reducing adverse effects. This presents a novel and promising treatment approach for clinical HCC therapy.
Materials and methods
In vitro cell studies
HepG2 (human liver cancer cell line) and LO-2 (human normal hepatic cell line) were procured from Type culture Collection of the Chinese Academy of sciences (Shanghai, China). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin at 37 °C, 5% CO2.
In vitro cell uptake assay
HepG2 and LO-2 cells, grown in 96-well plates (1 × 105 cells/well), were cultured for 24 h. After aspirating the medium, 100 μL of fresh medium containing free DOX, TRRP@DOX, or TRRP was added to each well, with DMEM as control. DOX concentration was 15 μg/mL in both free DOX and TRRP@DOX solutions, while TRRP concentration was 100 μg/mL. After 3 h, the medium was removed, and cells were washed with PBS. Cells were fixed with 4% formaldehyde for 30 min, stained with DAPI for 5 min, washed with PBS, and observed under a fluorescent microscope.
HepG2 and LO-2 cells (4 × 105 cells/well) were seeded in sterile 6-well plates and cultured for 24 h. After washing with PBS, cells were treated with TRRP, DOX, or TRRP@DOX (TRRP: 45 µg/mL, DOX: 15 µg/mL) for 2 h. Fluorescence intensity was measured using a flow cytometer with PE channel.
Cell-viability MTT assay
Cells (5 × 104 cells/well) were seeded in a 96-well plate and incubated for 24 h. They were then treated with varying concentrations of TRRP (0–75 µg), free DOX (0–25 µg), and TRRP@DOX (DOX concentrations ranging from 0 to 25 µg) for 12 h. Subsequently, cells were exposed to 5 mg/mL MTT solution and incubated for 4 h at 37 °C in the dark. Afterward, Formazan solution was added, and cells were further incubated for 4 h. Absorbance was measured at 570 nm using a microplate spectrophotometer. Triplicate experiments were performed for cell viability assays.
In vitro anti-tumor studies
1 × 105 HepG2 cells and LO-2 cells were seeded in a 6-well plate and incubated overnight. Afterward, the media were replaced by fresh complete media with TRRP, free DOX, and TRRP@DOX at an equivalent DOX dose of 15 µg for another 4 h. After being digested and resuspended, the cells were washed twice with PBS, which were then stained with Annexin-V-FITC (5 µL, excited at 488 nm) and 7-AAD (5 µL, excited at 546 nm) for 5 min in the dark. Finally, the degree of cell apoptosis was measured by a flow cytometer (Beckman Coulter, USA).
Orthotopic HCC rat model
The animal experiment proposal was approved by the board of the Animal Welfare Committee of the Chinese People’s Liberation Army General Hospital (KY-2021-11-23-1). Sprague Dawley (SD) rats weighing 220 ± 20 g were used. To establish the orthotopic McA-RH7777 rat model, 100 µL of McA-RH7777 cell suspension (5 × 106 cells in PBS) was injected into the left lateral lobe of the liver of each rat. Penicillin (2 × 105 units) and dexamethasone (2 mg) were intraperitoneally injected for 3 days post-transplantation to prevent infection and provide immunosuppression.
In vivo anti-HCC efficacy in HCC-bearing rats
In the McA-RH7777 rat syngeneic orthotopic HCC model intervention, the abdominal cavity was opened to identify and carefully dissect the hepatic and gastroduodenal arteries. The gastroduodenal artery was freed and sutures were placed at the proximal and distal ends. Following distal end ligation, a 26G indwelling needle (Jierui, China) was inserted into the gastroduodenal artery and advanced into the hepatic artery under direct vision. Different treatments were administered into the hepatic artery, including Control, Lipiodol, Lipiodol + DOX, and Lipiodol + TRRP@DOX (equivalent to 0.3 mg DOX), with 5 rats per group. After drug administration, the indwelling needles were removed and the near-end was sutured to stop bleeding.
On days 0, 3, and 7, all rats underwent mild anesthesia and were examined using a 3.0-T MR scanner (PharmaScan 70, Bruker). Fast-saturated T2-weighted images were acquired in transverse, with sequence parameters: TR/TE = 3158/33 ms, slice thickness = 1 mm, and matrix = 256 × 256. Tumor volume (V) was estimated using the largest (L) and smallest (S) diameters with the formula (1):
Tumor growth inhibition (TGI) rate is one of the most commonly used metrics to quantify the drug response of treatment groups compared to the control group [41]. The basic way to calculate TGI is following:
where V(T) and V(C) represent the mean tumor volume of treatment groups and the mean tumor volume of control at the same time after operation.
Caudal vein blood from SD rats was collected before and after treatments for 1, 3, and 7 days. Levels of ALT, AST, CREA, and CK were measured using an automatic biochemical analyzer (Toshiba) to assess hepatorenal function and myocardial toxicity.
On day 7, rats were euthanized, and tumor and major organ samples were collected for histological and IHC analysis. Samples were fixed in formalin, embedded in paraffin, and sectioned into 5 µm-thick slices. H&E staining was performed for general histology, while TUNEL and DAPI staining identified apoptotic cells. Anti-CD31 and anti-VEGF staining assessed angiogenesis, and anti-Ki67 staining evaluated tumor proliferation. Slides were analyzed with a TissueFAXS microscope, utilizing integrated optical density (IOD) for quantitative IHC analysis.
Statistical analysis
Each experiment was repeated three times, and the results were expressed as mean ± standard deviation statistical analysis was performed using the statistical t-test method. Data between different groups were compared via a one-way analysis of variance. The following P-values were considered statistically significant: P < 0.05:*, P < 0.01:**, P < 0.001:***.
Result
Cellular drug uptake and cytotoxicity of TRRP@DOX
In Fig. 1a, both HepG2 and LO-2 cells exhibited uptake of DOX, evidenced by similar fluorescence intensity. However, TRRP@DOX uptake differed significantly between the two cell types, with lower fluorescence observed in LO-2 cells compared to HepG2 cells, indicating targeted binding to tumor cells. As shown in Fig. 1b, in HepG2 cells, the DOX and TRRP@DOX groups were 26.18 ± 0.95 and 46.43 ± 0.62, respectively, while in LO-2 cells, the DOX and TRRP@DOX groups were 25.13 ± 0.36 and 9.47 ± 0.51, respectively. Statistical analysis revealed no significant difference between the HepG2 + DOX and LO-2 + DOX groups (P = 0.27 > 0.05) Statistical analysis revealed significant differences between groups (P < 0.0001).
PE channel was used to detect the average fluorescence intensity distribution of LO-2 cells for TRRP, TRRP@DOX, and DOX, as shown in Fig. 2a. TRRP@DOX notably reduced DOX uptake by LO-2 cells. Average fluorescence intensity of LO-2 cells co-cultured with TRRP, TRRP@DOX, and DOX was 110 ± 7, 153 ± 5, and 1098 ± 10, respectively (Fig. 2b). Statistical analysis indicated significantly lower fluorescence intensity in LO-2 cells after TRRP@DOX uptake compared to DOX uptake (P < 0.0001), demonstrating the effectiveness of TRRP@DOX in reducing DOX uptake by LO-2 cells.
PE channel was used to detect the average fluorescence intensity distribution of HepG2 cells for TRRP, TRRP@DOX, DOX, and TRRP@DOX + excess TRRP, as shown in Fig. 3a. TRRP@DOX notably increased DOX uptake by HepG2 cells. Additionally, upon adding excess TRRP, we observed a significant reduction in TRRP@DOX uptake by HepG2 cells. This suggests that TRRP competes with TRRP@DOX for TfR binding, thereby reducing TRRP@DOX uptake by HepG2 cells and indirectly demonstrating TRRP’s ability to target HepG2 cell surfaces overexpressing TfR. In Figs. 2, 3, 4, 5b, average fluorescence intensity of HepG2 cells after co-culturing with TRRP, TRRP@DOX, DOX, and TRRP@DOX + TRRP were 115 ± 5, 2785 ± 10, 1096 ± 6, and 168 ± 7, respectively. Statistical analysis showed significant differences between the TRRP@DOX group and the others (P < 0.0001).
MTT assay assessed the impact of TRRP, DOX, and TRRP@DOX on HepG2 and LO-2 cell viability (Fig. 4a). TRRP at concentrations of 0–75 µg/mL showed minimal toxicity after 24 h, indicating its excellent biosafety. Treatment with free DOX (0–25 µg/mL) revealed a dose-dependent decrease in cell viability, suggesting non-selective cellular death. Notably, TRRP@DOX treatment significantly reduced cell viability, particularly in HepG2 cells compared to LO-2 cells. Subsequently, flow cytometric analysis with Annexin V-FITC and 7-AAD staining quantified cell apoptosis (Fig. 4b). Consistently, TRRP@DOX induced stronger apoptosis in HepG2 cells than DOX, while LO-2 cells exhibited lower apoptosis with TRRP@DOX compared to DOX. These results highlight the tumor cell targeting ability of TRRP@DOX. Overall, our cytotoxicity experiments confirm that TRRP@DOX reduces toxicity to normal cells while enhancing cytotoxicity against tumor cells. These findings underscore the in vitro specific cytotoxicity of TRRP@DOX against tumor cells.
Therapeutic efficacy of TRRP@DOX emulsions in orthotopic rat Mca-RH-7777 syngeneic HCC model
The MRI examination of rats in the four groups is shown in Fig. 5b. T2-weighted imaging revealed uniform slightly high signal intensity with clear boundaries, no obvious satellite foci formation around the tumor, and no evidence of ascites formation. Preoperative tumor volumes for the control, Lipiodol, Lipiodol + DOX, and Lipiodol + TRRP@DOX groups were calculated using formula (1), as shown in Fig. 5c, yielding results of 69.67 ± 12.04 mm3, 72.62 ± 12.27 mm3, 77.36 ± 11.05 mm3, and 79.05 ± 7.35 mm3, respectively (p = 0.51 > 0.05). There was no statistical difference in preoperative tumor size among the four groups of rats with liver cancer models. Postoperatively at 3 days, the volumes were 92.48 ± 12.28 mm3, 75.78 ± 10.72 mm3, 68.62 ± 8.55 mm3, and 49.27 ± 6.05 mm3, respectively (p < 0.001), showing statistical differences in tumor size among the four groups at 3 days postoperatively. At 7 days postoperatively, the volumes were 122.48 ± 9.68 mm3, 57.89 ± 5.28 mm3, 55.89 ± 6.94 mm3, and 25.07 ± 9.82 mm3, respectively (p < 0.001), indicating statistical differences in tumor size among the four groups at 7 days postoperatively. The tumor growth inhibition rates for the Lipiodol, Lipiodol + DOX, and Lipiodol + TRRP@DOX groups at 3 days postoperatively were 21.67 ± 0.88%, 32.93 ± 1.15%, and 53.37 ± 1.14%, respectively, and at 7 days postoperatively were 54.63 ± 1.03%, 58.80 ± 1.32%, and 81.96 ± 1.64%, respectively. The results of TGI indicate that the Lipiodol + TRRP@DOX group exhibited significantly better efficacy compared to the other groups, demonstrating that TRRP@DOX treatment significantly inhibited tumor growth.
Drug safety is one of the main factors that influence clinical HCC treatment decisions. The toxicity of DOX mainly includes cardiac toxicity, renal toxicity and damage to liver function (Fig. 6a). After embolization, ALT and AST levels of Lipiodol + DOX group increased obviously on day 1 and decreased to normal on day 7, indicating some impairment of liver function. In comparison, the ALT and AST in the lipiodol + DOX group were constantly low and within the normal range from day 1 to day 7, certifying its high safety. Moreover, all the treatment caused negligible damage to the kidney, as supported by normal CREA levels. CK levels of lipiodol + DOX group were higher than those other groups on day 7, indicating myocardial damage. In Lipiodol + TRRP@DOX group, the H&E staining of the heart in this group also proved this point (Fig. 6b). H&E staining of heart, liver, spleen, lung, and kidney tissues showed no significant organ damage on day 7. However, it is noteworthy that metastatic tumors were observed in the lung tissues of all three groups (Control, lipiodol, and lipiodol + DOX); notably, in Lipiodol + TRRP@DOX group, no tumor tissues were observed. This observation underscores the tumor-targeting ability of TRRP@DOX, emphasizing its superior overall efficacy in combating hepatocellular carcinoma. These findings indicate that TRRP@DOX is safe and has a high potential for clinical applications.
To further evaluate the therapeutic effects, we euthanized the rats with 7 days treatment and collect tumor tissues for histological analysis. H&E staining results showed that the tumor of Lipiodol + TRRP@DOX group had a higher degree of tumor necrosis than other three groups. TUNEL, CD31, VEGF, and Ki 67 immunohistochemical staining further revealed tumor cell apoptosis, angiogenesis, and proliferation, and the representative images are shown in Fig. 7a. The TUNEL-positive rates of tumor tissues in the lipiodol alone group, lipiodol + DOX group, and lipiodol + TRRP@DOX group 7 days postoperatively were 4.33 ± 0.57%, 8.8 ± 0.44%, 15.77 ± 0.46%, and 26.27 ± 0.68%, respectively. Further statistical analysis showed that TRRP@DOX had the highest induction of tumor cell apoptosis (P < 0.0001) compared to the other three groups. The expression rates of CD31 in tumor tissues of the lipiodol alone group, lipiodol + DOX group, and lipiodol + TRRP@DOX group 7 days postoperatively were 2.33 ± 0.40%, 9.46 ± 1.22%, 5.76 ± 0.45%, and 1.53 ± 0.25%, respectively, indicating that TRRP@DOX + lipiodol group had lower tumor microvessel density compared to the lipiodol group (P < 0.0001) and the lipiodol + DOX group (P < 0.001). The expression rates of VEGF in tumor tissues of the lipiodol alone group, lipiodol + DOX group, and lipiodol + TRRP@DOX group 7 days postoperatively were 1.70 ± 0.40%, 6.46 ± 0.32%, 4.43 ± 0.32%, and 0.86 ± 0.40%, respectively, indicating that TRRP@DOX could inhibit neovascularization compared to the lipiodol group (P < 0.0001) and the lipiodol + DOX group (P < 0.0001). The expression rates of Ki 67 in tumor tissues of the lipiodol alone group, lipiodol + DOX group, and lipiodol + TRRP@DOX group 7 days postoperatively were 34.96 ± 0.30%, 26.13 ± 0.83%, 24.43 ± 0.32%, and 0.08 ± 0.04%, respectively, indicating that TRRP@DOX could effectively inhibit tumor proliferation compared to the other three groups (P < 0.0001). Biochemical indicators detected at regular intervals postoperatively suggested that TRRP@DOX did not cause systemic toxic side effects. Pathological examination results 7 days postoperatively showed no tumor metastasis or significant organ damage in the TRRP@DOX group.
Discussion
In real-world scenarios, liver cancer often eludes early detection, resulting in diagnosis at advanced stages, with fewer than 20% of patients qualifying for surgery [4]. Transarterial chemoembolization (TACE) stands as the preferred treatment for intermediate to advanced liver cancer by delivering a blend of iodized oil and chemotherapeutic drugs directly to tumor-feeding arteries, inducing localized chemotherapy embolization. Despite TACE’s recognized efficacy, challenges persist, notably the systemic release of chemotherapy agents like DOX during injection and embolization, leading to systemic toxicity. Addressing these challenges and enhancing drug targeting in TACE have emerged as crucial pursuits in liver cancer treatment.
TRRP, synthesized in this study, forms disulfide bonds via cysteine residues, facilitating controlled drug release under high glutathione (GSH) concentrations found in tumor cells. While TRRP@DOX releases less than 10% of drugs within 24 h under plasma and normal cell GSH levels, it reaches 65% release within 24 h under tumor cell-equivalent GSH concentrations. Fluorescence microscopy and flow cytometry confirmed specific uptake of TRRP@DOX by HepG2 cells compared to LO-2 cells. Moreover, excess TRRP competitively reduced TRRP@DOX uptake, highlighting the role of TRRP-TfR binding in specific cell uptake. This indirectly proves that TRRP@DOX is specifically uptaked by tumor cells through TfR.
Both MTT assay and flow cytometry demonstrated no cytotoxicity from TRRP, consistent with expectations, affirming TRRP’s suitability as a drug carrier. Subsequent experiments validated TRRP@DOX’s targeted killing of tumor cells while minimizing toxicity to normal cells like LO-2 cells. The targeted uptake of TRRP@DOX by liver cancer cells underscores its efficacy. Notably, tumor cells exhibit higher GSH concentrations than normal cells, enabling controlled drug release from TRRP@DOX within tumor cells’ specific intracellular environments.
In rat liver cancer models, hepatic artery administration of iodized oil and TRRP@DOX yielded tumor growth inhibition rates of 53.37 and 81.96% after 3 and 7 days post-operation, respectively. In contrast, hepatic artery injection of iodized oil and DOX resulted in lower inhibition rates of 32.93 and 58.80%, respectively, underscoring the superior efficacy of TRRP@DOX. Generally, a tumor inhibition rate exceeding 40% indicates effective treatment. Additionally, except for the Lipiodol + TRRP@DOX group, varying degrees of pulmonary tumor metastasis were observed in the other three groups, with the control group exhibiting the most severe metastasis and the Lipiodol + DOX group the least.
The occurrence of pulmonary tumor metastasis in the Lipiodol + DOX group may stem from the iodized oil DOX emulsion’s instability, resulting in rapid drug release. Conversely, TRRP@DOX’s slow release profile maintains high local drug concentrations, effectively inhibiting tumor proliferation and systemic metastasis. This study’s approach mimics the clinical TACE strategy, combining TRRP@DOX with iodized oil, overcoming potential embolization limitations due to TRRP@DOX’s small particle size. Through comparison with iodized oil + DOX, this study underscores TRRP@DOX’s enhanced efficacy and reduced systemic toxicity, highlighting its promise in liver cancer treatment.
Conclusions
TRRP exhibits excellent biocompatibility and forms TRRP@DOX nanoparticles with DOX, allowing targeted uptake by liver cancer cells and controlled release of DOX under intracellular reducing conditions. TRRP@DOX effectively inhibits tumor growth compared to DOX alone while reducing systemic toxicity. This study introduces a promising drug delivery strategy for clinical TACE treatment of liver cancer, with significant implications for future research.
Data availability
The datasets generated during and analysed during the current study are available from the corresponding author on reasonable request.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021, 71(3): 209-249. https://doi.org/10.3322/caac.21660
Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer 2020, 1873(1): 188314. https://doi.org/10.1016/j.bbcan.2019.188314
Hepatocellular carcinoma. Nat Rev Dis Primers 2021, 7(1): 7. https://doi.org/10.1038/s41572-021-00245-6
Thomas CE, Luu HN, Wang R, Xie G, Adams-Haduch J, Jin A, Koh WP, Jia W, Behari J, Yuan JM. Association between Pre-Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study. Cancers (Basel) 2021, 13(11). https://doi.org/10.3390/cancers13112648
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology 2021, 73 Suppl 1(Suppl 1): 4-13. https://doi.org/10.1002/hep.31288
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 2020, 6(11): e204564. https://doi.org/10.1001/jamaoncol.2020.4564
Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019, 12: 1629-1640. https://doi.org/10.2147/OTT.S196713
Elnaggar MH, Abushouk AI, Hassan AHE, Lamloum HM, Benmelouka A, Moatamed SA, Abd-Elmegeed H, Attia S, Samir A, Amr N, Johar D, Zaky S. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma. Semin Cancer Biol 2021, 69: 91-99. https://doi.org/10.1016/j.semcancer.2019.08.016
Kumar V, Rahman M, Gahtori P, Al-Abbasi F, Anwar F, Kim HS. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Expert Opin Drug Deliv 2021, 18(6): 673-694. https://doi.org/10.1080/17425247.2021.1860939
Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D’Angelica MI, Allen PJ, Erinjeri JP, Brody LA, O’Neill GP, Johnson KN, Garcia AR, Beattie C, Zhao B, Solomon SB, Schwartz LH, DeMatteo R, Abou-Alfa GK. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol 2016, 34(17): 2046-2053. https://doi.org/10.1200/JCO.2015.64.0821
Wang YX, De Baere T, Idee JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015, 27(2): 96-121. https://doi.org/10.3978/j.issn.1000-9604.2015.03.03
Wu H, Wang MD, Liang L, Xing H, Zhang CW, Shen F, Huang DS, Yang T. Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management. Small 2021, 17(6): e2005236. https://doi.org/10.1002/smll.202005236
Sheth RA, Wen X, Li J, Melancon MP, Ji X, Wang YA, Hsiao CH, Chow DS, Whitley EM, Li C, Gupta S. Doxorubicin-loaded hollow gold nanospheres for dual photothermal ablation and chemoembolization therapy. Cancer Nanotechnol 2020, 11(1). https://doi.org/10.1186/s12645-020-00062-8
Wang D, Wu Q, Guo R, Lu C, Niu M, Rao W. Magnetic liquid metal loaded nano-in-micro spheres as fully flexible theranostic agents for SMART embolization. Nanoscale 2021, 13(19): 8817-8836. https://doi.org/10.1039/d1nr01268a
Chen Q, Ke H, Dai Z, Liu Z. Nanoscale theranostics for physical stimulus-responsive cancer therapies. Biomaterials 2015, 73: 214-230. https://doi.org/10.1016/j.biomaterials.2015.09.018
Huang D, Dai H, Tang K, Chen B, Zhu H, Chen D, Li N, Wang Y, Liu C, Huang Y, Yang J, Zhang C, Lin R, He W. A versatile UCST-type composite microsphere for image-guided chemoembolization and photothermal therapy against liver cancer. Nanoscale 2020, 12(38): 20002-20015. https://doi.org/10.1039/d0nr04592f
Zhou J, Ling G, Cao J, Ding X, Liao X, Wu M, Zhou X, Xu H, Long Q. Transcatheter Intra-Arterial Infusion Combined with Interventional Photothermal Therapy for the Treatment of Hepatocellular Carcinoma. Int J Nanomedicine 2020, 15: 1373-1385. https://doi.org/10.2147/IJN.S233989
Li X, Yuan HJ, Tian XM, Tang J, Liu LF, Liu FY. Biocompatible copper sulfide-based nanocomposites for artery interventional chemo-photothermal therapy of orthotropic hepatocellular carcinoma. Mater Today Bio 2021, 12: 100128. https://doi.org/10.1016/j.mtbio.2021.100128
Niu S, Zhang X, Williams GR, Wu J, Gao F, Fu Z, Chen X, Lu S, Zhu LM. Hollow Mesoporous Silica Nanoparticles Gated by Chitosan-Copper Sulfide Composites as Theranostic Agents for the Treatment of Breast Cancer. Acta Biomater 2021, 126: 408-420. https://doi.org/10.1016/j.actbio.2021.03.024
Wen J, Chen Q, Ye L, Zhang H, Zhang A, Feng Z. The preparation of pH and GSH dual responsive thiolated heparin/DOX complex and its application as drug carrier. Carbohydr Polym 2020, 230: 115592. https://doi.org/10.1016/j.carbpol.2019.115592
Liu F, Li X, Li Y, Qi Y, Yuan H, He J, Li W, Zhou M. Designing pH-triggered drug release iron oxide nanocomposites for MRI-guided photothermal-chemoembolization therapy of liver orthotopic cancer. Biomaterials science 2019, 7(5): 1842-1851. https://doi.org/10.1039/c9bm00056a
Fan X, Yuan Z, Shou C, Fan G, Wang H, Gao F, Rui Y, Xu K, Yin P. cRGD-Conjugated Fe(3)O(4)@PDA-DOX Multifunctional Nanocomposites for MRI and Antitumor Chemo-Photothermal Therapy. Int J Nanomedicine 2019, 14: 9631-9645. https://doi.org/10.2147/IJN.S222797
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015, 33(9): 941-951. https://doi.org/10.1038/nbt.3330
Li R, Peng F, Cai J, Yang D, Zhang P. Redox dual-stimuli responsive drug delivery systems for improving tumor-targeting ability and reducing adverse side effects. Asian Journal of Pharmaceutical Sciences 2020, 15(3): 311-325. https://doi.org/10.1016/j.ajps.2019.06.003
Ding Y, Ting JP, Liu J, Al-Azzam S, Pandya P, Afshar S. Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics. Amino Acids 2020, 52(9): 1207-1226. https://doi.org/10.1007/s00726-020-02890-9
Wang H, Feng Z, Xu B. Assemblies of Peptides in a Complex Environment and their Applications. Angewandte Chemie (International ed in English) 2019, 58(31): 10423-10432. https://doi.org/10.1002/anie.201814552
Dhawan S, Ghosh S, Ravinder R, Bais SS, Basak S, Krishnan NMA, Agarwal M, Banerjee M, Haridas V. Redox Sensitive Self-Assembling Dipeptide for Sustained Intracellular Drug Delivery. Bioconjug Chem 2019, 30(9): 2458-2468. https://doi.org/10.1021/acs.bioconjchem.9b00532
Mohan P, Rapoport N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharm 2010, 7(6): 1959-1973. https://doi.org/10.1021/mp100269f
Zhang J, Wang X, Cheng L, Yuan J, Zhong Z. SP94 peptide mediating highly specific and efficacious delivery of polymersomal doxorubicin hydrochloride to hepatocellular carcinoma in vivo. Colloids Surf B Biointerfaces 2021, 197: 111399. https://doi.org/10.1016/j.colsurfb.2020.111399
Du B, Han H, Wang Z, Kuang L, Wang L, Yu L, Wu M, Zhou Z, Qian M. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide. Mol Cancer Res 2010, 8(2): 135-144. https://doi.org/10.1158/1541-7786.MCR-09-0339
Dai X, Xiong Y, Xu D, Li L, Su Z, Zhang Q, Zheng Q. TfR Binding Peptide Screened by Phage Display Technology - Characterization to Target Cancer Cells. Tropical Journal of Pharmaceutical Research 2014, 13(3). https://doi.org/10.4314/tjpr.v13i3.3
Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 2002, 22(3): 225-250. https://doi.org/10.1002/med.10008
Xu Y, Liu SY, Zeng L, Ma H, Zhang Y, Yang H, Liu Y, Fang S, Zhao J, Xu Y, Ashby CR, Jr., He Y, Dai Z, Pan Y. An Enzyme-Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis-Based Synergistic Cancer Therapy. Adv Mater 2022, 34(43): e2204733. https://doi.org/10.1002/adma.202204733
Chen M, Liu D, Liu F, Wu Y, Peng X, Song F. Recent advances of redox-responsive nanoplatforms for tumor theranostics. J Control Release 2021, 332: 269-284. https://doi.org/10.1016/j.jconrel.2021.02.030
Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002, 54(4): 561-587. https://doi.org/10.1124/pr.54.4.561
Kawabata H. Transferrin and transferrin receptors update. Free Radic Biol Med 2019, 133: 46-54. https://doi.org/10.1016/j.freeradbiomed.2018.06.037
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021, 6(1): 201. https://doi.org/10.1038/s41392-021-00572-w
Hu X, He Y, Han Z, Liu W, Liu D, Zhang X, Chen L, Qi L, Chen L, Luo Y, Li Q, Chen P, Wu Q, Zhu X, Guo H. PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma. Cell Death Dis 2022, 13(11): 1010. https://doi.org/10.1038/s41419-022-05448-7
Huang D, Xu D, Chen W, Wu R, Wen Y, Liu A, Lin L, Lin X, Wang X. Fe-MnO(2) nanosheets loading dihydroartemisinin for ferroptosis and immunotherapy. Biomed Pharmacother 2023, 161: 114431. https://doi.org/10.1016/j.biopha.2023.114431
Sinha NJ, Langenstein MG, Pochan DJ, Kloxin CJ, Saven JG. Peptide Design and Self-assembly into Targeted Nanostructure and Functional Materials. Chem Rev 2021, 121(22): 13915-13935. https://doi.org/10.1021/acs.chemrev.1c00712
Li Q, Dai W, Liu J, Li YX, Li YY. DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models. J Transl Med 2019, 17(1): 39. https://doi.org/10.1186/s12967-019-1785-7
Funding
This work was supported by National Natural Science Foundation of China (82172038).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
The study was approved by the Ethics Committee of Chinese PLA general hospital. (KY-2021–11-23–1).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Xia, Y., Li, X. & Liu, F. Targeted redox-responsive peptide for arterial chemoembolization therapy of orthotropic hepatocellular carcinoma. Abdom Radiol (2024). https://doi.org/10.1007/s00261-024-04481-8
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00261-024-04481-8